|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilson TA, Karajannis MA and Harter DH:
Glioblastoma multiforme: State of the art and future therapeutics.
Surg Neurol Int. 5:642014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trivedi R and Mishra DP: Trailing TRAIL
resistance: Novel targets for TRAIL sensitization in cancer cells.
Front Oncol. 5:692015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hodgkinson CP, Gomez JA, Mirotsou M and
Dzau VJ: Genetic engineering of mesenchymal stem cells and its
application in human disease therapy. Hum Gene Ther. 21:1513–1526.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Müller FJ, Snyder EY and Loring JF: Gene
therapy: Can neural stem cells deliver? Nat Rev Neurosci. 7:752006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng S, Nethi SK, Rathi S, Layek B and
Prabha S: Engineered mesenchymal stem cells for targeting solid
tumors: Therapeutic potential beyond regenerative therapy. J
Pharmacol Exp Ther. 370:231–241. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu F and Zhu JH: Stem cells tropism for
malignant gliomas. Neurosci Bull. 23:363–369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Menon LG, Picinich S, Koneru R, Gao H, Lin
SY, Koneru M, Mayer-Kuckuk P, Glod J and Banerjee D: Differential
gene expression associated with migration of mesenchymal stem cells
to conditioned medium from tumor cells or bone marrow cells. Stem
Cells. 25:520–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menon LG, Kelly K, Yang HW, Kim SK, Black
PM and Carroll RS: Human bone marrow-derived mesenchymal stromal
cells expressing S-TRAIL as a cellular delivery vehicle for human
glioma therapy. Stem Cells. 27:2320–2330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SM, Kim DS, Jeong CH, Kim DH, Kim JH,
Jeon HB, Kwon SJ, Jeun SS, Yang YS, Oh W and Chang JW: CXC
chemokine receptor 1 enhances the ability of human umbilical cord
blood-derived mesenchymal stem cells to migrate toward gliomas.
Biochem Biophys Res Commun. 407:741–746. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SA, Ryu CH, Kim SM, Lim JY, Park SI,
Jeong CH, Jun J, Oh JH, Park SH, Oh W and Jeun SS:
CXCR4-transfected human umbilical cord blood-derived mesenchymal
stem cells exhibit enhanced migratory capacity toward gliomas. Int
J Oncol. 38:97–103. 2011.PubMed/NCBI
|
|
13
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dimberg LY, Anderson CK, Camidge R,
Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful
cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene. 32:1341–1350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JY, Kim EH, Kim SU, Kwon TK and Choi
KS: Capsaicin sensitizes malignant glioma cells to TRAIL-mediated
apoptosis via DR5 upregulation and survivin downregulation.
Carcinogenesis. 31:367–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Son YG, Kim EH, Kim JY, Kim SU, Kwon TK,
Yoon AR, Yun CO and Choi KS: Silibinin sensitizes human glioma
cells to TRAIL-mediated apoptosis via DR5 up-regulation and
down-regulation of c-FLIP and survivin. Cancer Res. 67:8274–8284.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim SM, Oh JH, Park SA, Ryu CH, Lim JY,
Kim DS, Chang JW, Oh W and Jeun SS: Irradiation enhances the tumor
tropism and therapeutic potential of tumor necrosis factor-related
apoptosis-inducing ligand-secreting human umbilical cord
blood-derived mesenchymal stem cells in glioma therapy. Stem Cells.
28:2217–2228. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fröscher W, Schulz H and Gugler R:
Valproic acid in the treatment of epilepsy with special emphasis on
serum level determination (author's transl). Fortschr Neurol
Psychiatr Grenzgeb. 46:327–341. 1978.(In German). PubMed/NCBI
|
|
20
|
Cipriani A, Reid K, Young AH, Macritchie K
and Geddes J: Valproic acid, valproate and divalproex in the
maintenance treatment of bipolar disorder. Cochrane Database Syst
Rev. 10:CD0031962013.
|
|
21
|
Valiyaveettil D, Malik M, Joseph DM, Ahmed
SF, Kothwal SA and Vijayasaradhi M: Effect of valproic acid on
survival in glioblastoma: A prospective single-arm study. South
Asian J Cancer. 7:159–162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Searles CD, Slesinger PA and Singer HS:
Effects of anticonvulsants on cholinergic and GABAergic properties
in the neuronal cell clone NG108-15. Neurochem Res. 13:1007–1013.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tarasenko N, Cutts SM, Phillips DR,
Berkovitch-Luria G, Bardugo-Nissim E, Weitman M, Nudelman A and
Rephaeli A: A novel valproic acid prodrug as an anticancer agent
that enhances doxorubicin anticancer activity and protects normal
cells against its toxicity in vitro and in vivo. Biochem Pharmacol.
88:158–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gotfryd K, Skladchikova G, Lepekhin EA,
Berezin V, Bock E and Walmod PS: Cell type specific anti-cancer
properties of valproic acid independent effects on HDAC activity
and Erk12 phosphorylation. BMC Cancer. 10:3832010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu W, Parmigiani R and Marks P: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Coco FL, Nervi C, Pelicci PG and
Heinzel T: Valproic acid defines a novel class of HDAC inhibitors
inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chateauvieux S, Morceau F, Dicato M and
Diederich M: Molecular and therapeutic potential and toxicity of
valproic acid. J Biomed Biotechnol. 2010:4793642010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim SM, Lim JY, Park SI, Jeong CH, Oh JH,
Jeong M, Oh W, Park SH, Sung YC and Jeun SS: Gene therapy using
TRAIL-secreting human umbilical cord blood-derived mesenchymal stem
cells against intracranial glioma. Cancer Res. 68:9614–9623. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH,
Jun JA, Oh JH, Park SH, Oh WI and Jeun SS: Migration of human
umbilical cord blood mesenchymal stem cells mediated by stromal
cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal
transduction pathways. Biochem Biophys Res Commun. 398:105–110.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD
and Jeun SS: Potential application of temozolomide in mesenchymal
stem cell-based TRAIL gene therapy against malignant glioma. Stem
Cells Transl Med. 3:172–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Janssen CF, Maiello P, Wright MJ Jr,
Kracinovsky KB and Newsome JT: Comparison of atipamezole with
yohimbine for antagonism of xylazine in mice anesthetized with
ketamine and xylazine. J Am Assoc Lab Anim Sci. 56:142–147.
2017.PubMed/NCBI
|
|
32
|
Danneman PJ, Stein S and Walshaw SO:
Humane and practical implications of using carbon dioxide mixed
with oxygen for anesthesia or euthanasia of rats. Lab Anim Sci.
47:376–385. 1997.PubMed/NCBI
|
|
33
|
Carpenter J and Chris M: Exotic animal
formulary. (5th edition). pp4682017.
|
|
34
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Naderi-Meshkin H, Bahrami AR, Bidkhori HR,
Mirahmadi M and Ahmadiankia N: Strategies to improve homing of
mesenchymal stem cells for greater efficacy in stem cell therapy.
Cell Biol Int. 39:23–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rosato RR, Almenara JA, Dai Y and Grant S:
Simultaneous activation of the intrinsic and extrinsic pathways by
histone deacetylase (HDAC) inhibitors and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) synergistically
induces mitochondrial damage and apoptosis in human leukemia cells.
Mol Cancer Ther. 2:1273–1284. 2003.PubMed/NCBI
|
|
37
|
Frew AJ, Lindemann RK, Martin BP, Clarke
CJ, Sharkey J, Anthony DA, Banks K-M, Haynes NM, Gangatirkar P,
Stanley K, et al: Combination therapy of established cancer using a
histone deacetylase inhibitor and a TRAIL receptor agonist. Proc
Natl Acad Sci USA. 105:11317–11322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bangert A, Cristofanon S, Eckhardt I,
Abhari BA, Kolodziej S, Häcker S, Vellanki SHK, Lausen J, Debatin
KM and Fulda S: Histone deacetylase inhibitors sensitize
glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated
downregulation of cFLIP. Oncogene. 31:4677–4688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakamizo A, Marini F, Amano T, Khan A,
Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et
al: Human bone marrow-derived mesenchymal stem cells in the
treatment of gliomas. Cancer Res. 65:3307–3318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Faderl S, O'Brien S, Pui CH, Stock W,
Wetzler M, Hoelzer D and Kantarjian HM: Adult acute lymphoblastic
leukemia: Concepts and strategies. Cancer. 116:1165–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Marquez-Curtis LA and Janowska-Wieczorek
A: Enhancing the migration ability of mesenchymal stromal cells by
targeting the SDF-1/CXCR4 axis. Biomed Res Int. 2013:5610982013.
View Article : Google Scholar : PubMed/NCBI
|
